4-(3-{[6-(2-hydroxy-2-methylpropoxy)pyridin-3-yl]methyl}-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile | 1273068-71-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 4-(3-{[6-(2-hydroxy-2-methylpropoxy)pyridin-3-yl]methyl}-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile
• 英文别名: 4-(3-((6-(2-Hydroxy-2-methylpropoxy)pyridin-3-yl)methyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile；4-[3-[[6-(2-hydroxy-2-methylpropoxy)pyridin-3-yl]methyl]-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile
• CAS: 1273068-71-5
• 化学式: C₂₃H₂₃F₃N₄O₃S
• 分子量: 492.522
• InChiKey: WVDXRFHMLCQHHK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  34
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  122
• 氢给体数：
  1
• 氢受体数：
  9

文献信息

• [EN] SUSTITUTED ( HETEROARYLMETHYL ) THIOHYDANTOINS AS ANTICANCER DRUGS<br/>[FR] THIOHYDANTOÏNES (HÉTÉROARYLMÉTHYL) SUBSTITUÉES UTILISÉES COMME MÉDICAMENTS ANTICANCÉREUX
  申请人：BAYER SCHERING PHARMA AG

  公开号：WO2011029537A1

  公开（公告）日：2011-03-17

  The invention relates to substituted (heteroarylmethyl) thiohydantoin compounds of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, and their use for the preparation of medicaments for the treatment and/or prophylaxis of disorders, in particular of prostate cancer.

  这项发明涉及一般式（I）所述和定义的取代（杂环烷基）硫代恶唑酮化合物，以及它们的制备方法，它们用于治疗和/或预防疾病的用途，以及它们用于制备药物以治疗和/或预防疾病，特别是前列腺癌。
• Substituted (Heteroarylmethyl)thiohydantoins
  申请人：Lücking Ulrich

  公开号：US20120251551A1

  公开（公告）日：2012-10-04

  The invention relates to substituted (heteroarylmethyl) thiohydantoin compounds of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, and their use for the preparation of medicaments for the treatment and/or prophylaxis of disorders, in particular of prostate cancer.

  本发明涉及一般式（I）所描述和定义的取代（杂环芳基甲基）硫脲化合物，以及它们的制备方法，它们的用途用于治疗和/或预防疾病，以及它们的用途用于制备用于治疗和/或预防疾病的药物，特别是前列腺癌。
• (Heteroarylmethyl) Thiohydantoins as anticancer drugs
  申请人：Cleve Arwed

  公开号：US20120238533A1

  公开（公告）日：2012-09-20

  The invention refers to the use of androgen receptor antagonists for the treatment and/or prevention of fibroids, also known as uterine leiomyoma, leiomyomata. Particularly, the invention refers to the use of an androgen receptor antagonist being any one of the compounds according to the following list: cyproterone acetate, oxendolone, chlormadinone acetate, spironolactone, osaterone acetate, dienogest, flutamide, hydroxyflutamide, nilutamide, bicalutamide, RU 58841, LGD-2226, MDV3100, BMS-641988, BMS-779333, or 4-(3-[6-(2-hydroxy-2-methylpropoxy)pyridin-3-yl]methyl}-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile (thioxoimidazolidine derivative) for the treatment of fibroids.

  本发明涉及雄激素受体拮抗剂用于治疗和/或预防纤维瘤，也称为子宫肌瘤，平滑肌瘤。特别地，本发明涉及使用雄激素受体拮抗剂，包括以下列表中的任何一种化合物：醋酸环丙孕酮，氧炔诺龙，醋酸氯甲酮，螺内酯，醋酸奥沙泰龙，双炔诺孕酮，氟他胺，羟基氟他胺，尼鲁特胺，比卡鲁胺，RU 58841，LGD-2226，MDV3100，BMS-641988，BMS-779333，或4-（3-[6-（2-羟基-2-甲基丙氧基）吡啶-3-基]甲基}-4,4-二甲基-5-氧代-2-噻唑烷-1-基）-2-（三氟甲基）苯甲腈（噻唑烷衍生物）用于治疗纤维瘤。
• SUSTITUTED ( HETEROARYLMETHYL ) THIOHYDANTOINS AS ANTICANCER DRUGS
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：EP2475653A1

  公开（公告）日：2012-07-18
• SUBSTITUTED (HETEROARYLMETHYL) THIOHYDANTOINS AS ANTICANCER DRUGS
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：EP2475366A1

  公开（公告）日：2012-07-18